NCT07554339 A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015) Status NOT_YET_RECRUITING Phase PHASE3
NCT07531095 Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) Status RECRUITING Phase PHASE1
NCT07511504 Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma Status NOT_YET_RECRUITING Phase PHASE2
NCT07507968 TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma Status NOT_YET_RECRUITING Phase PHASE2
NCT07459634 A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC Status NOT_YET_RECRUITING Phase PHASE2
NCT07361497 A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) Status RECRUITING Phase PHASE3
NCT07339059 Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Status RECRUITING Phase PHASE2
NCT07332351 Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial Status NOT_YET_RECRUITING Phase PHASE2
NCT07288034 Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial Status RECRUITING Phase PHASE2
NCT07247786 Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT) Status NOT_YET_RECRUITING Phase PHASE2
NCT07226063 Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer Status NOT_YET_RECRUITING Phase PHASE2
NCT07221253 A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) Status RECRUITING Phase PHASE3
NCT07195695 Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations Status RECRUITING Phase PHASE3
NCT07174583 A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer Status RECRUITING Phase PHASE1/PHASE2
NCT07174570 Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer Status RECRUITING Phase PHASE2
NCT07166406 Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial Status RECRUITING Phase PHASE3
NCT07146230 The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2 Status NOT_YET_RECRUITING Phase PHASE2
NCT07122089 Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis Status RECRUITING Phase PHASE2
NCT07107750 Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer Status RECRUITING Phase PHASE1
NCT07081633 Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma Status ACTIVE_NOT_RECRUITING Phase PHASE2